Comparative Pharmacology
Head-to-head clinical analysis: OMNITROPE versus SEROSTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNITROPE versus SEROSTIM.
OMNITROPE vs SEROSTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased IGF-1 synthesis and metabolic effects including linear growth, protein synthesis, and lipolysis.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
0.005 mg/kg subcutaneously once daily initially, titrated to 0.005-0.01 mg/kg/day based on clinical response and IGF-1 levels.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
None Documented
None Documented
IV: ~0.5 hours; subcutaneous: ~3 hours (terminal). Clinical context: Duration of growth promotion requires daily dosing due to rapid clearance.
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Renal: ~70% as intact somatropin; fecal and biliary excretion are negligible.
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Category C
Category C
Growth Hormone
Growth Hormone